Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00841373 · ClinicalTrials.gov registry record · Phase 1

Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease

A Phase 1 study of Retinal Ischemia, sponsored by Southern New England Retina Associates.

Completed
Registry status
Phase 1
Development phase
1
Enrollment target
1
Study location

NCT00841373: Completed Phase 1 study of Retinal Ischemia, sponsored by Southern New England Retina Associates.

NCT00841373 is a Phase 1 study of Retinal Ischemia that has completed, run by Southern New England Retina Associates. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00841373, a Phase 1 study of Retinal Ischemia, has completed, sponsored by Southern New England Retina Associates.

COMPLETED
Registry status
Phase 1
Development phase
1 participants
Enrollment target
1
Study location

Study Summary

The object of the study is to compare treatment of iris/angle neovascularization with panretinal photocoagulation (laser) to treatment with panretinal photocoagulation and an anti-angiogenic drug: ranibizumab.

Conditions Studied

Interventions

  • PROCEDURE Panretinal Photocoagulation
  • PROCEDURE Panretinal Photocoagulation and intravitreal injection of ranibizumab

Study Locations (1)

Rhode Island

  • Southern New England Retina Associates - Providence

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2007-07
Est. Completion 2010-01
Phase Phase 1

What the finished NCT00841373 record still lists

NCT00841373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Retinal Ischemia appearing as the primary indexed condition, and to 2 interventions - of which Panretinal Photocoagulation is the first listed.

NCT00841373 reports a single indexed study location in Rhode Island.

Frequently Asked Questions

What is clinical trial NCT00841373 about?

NCT00841373 is a clinical study titled "Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease". The object of the study is to compare treatment of iris/angle neovascularization with panretinal photocoagulation (laser) to treatment with panretinal photocoagulation and an anti-angiogenic drug: ranibizumab.

What is the current status of trial NCT00841373?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2007-07. Estimated completion is 2010-01.

What conditions does trial NCT00841373 study?

This clinical trial studies the following conditions: Retinal Ischemia.

What interventions are being tested in trial NCT00841373?

The interventions under investigation include: Panretinal Photocoagulation (PROCEDURE), Panretinal Photocoagulation and intravitreal injection of ranibizumab (PROCEDURE).

Who is sponsoring clinical trial NCT00841373?

This trial is sponsored by Southern New England Retina Associates, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00841373 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT00841373's enrollment target sits among peer trials

1 2001st of 2000 the lowest of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00841373, the US trial registry maintained by the National Library of Medicine. NCT00841373 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.